Page last updated: 2024-11-05

2,6-lutidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-Lutidine, also known as 2,6-dimethylpyridine, is a colorless, flammable liquid with a pungent odor. It is a derivative of pyridine with two methyl groups at positions 2 and 6. 2,6-Lutidine is synthesized through various methods, including the reaction of 2,6-dimethylphenol with ammonia and the catalytic hydrogenation of 2,6-dimethylnitrobenzene. It is a versatile compound with applications in various fields. For instance, it is used as a solvent in organic synthesis, a catalyst in various reactions, and a precursor for the production of pharmaceuticals and agrochemicals. The compound's unique properties, such as its basicity and its ability to form coordination complexes with metal ions, make it an interesting subject of research in fields like catalysis and coordination chemistry. The study of 2,6-lutidine can lead to the development of new and improved catalysts for various chemical reactions and the synthesis of new compounds with unique properties. '

2,6-dimethylpyridine : A member of the class of methylpyridines that is pyridine carrying methyl substituents at positions 2 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7937
CHEMBL ID22976
CHEBI ID32548
SCHEMBL ID9611
MeSH IDM0060589

Synonyms (77)

Synonym
AC-5116
EN300-19113
108-48-5
.alpha.,.alpha.'-lutidine
nsc2155
2,6-dimethylpyridine
nsc-2155
.alpha.,.alpha.'-dimethylpyridine
2,6-lutidine
ai3-24282
hsdb 79
2,6-dimethypyridine
fema no. 3540
nsc 2155
einecs 203-587-3
AC-907/25014177
alpha,alpha'-dimethylpyridine
LUT ,
alpha,alpha'-lutidine
lutidine
CHEBI:32548 ,
pyridine, 2,6-dimethyl-
inchi=1/c7h9n/c1-6-4-3-5-7(2)8-6/h3-5h,1-2h
2,6-dimethylpyridine, >=99%
2,6-lutidine, reagentplus(r), 98%
2,6-lutidine, purified by redistillation, >=99%
CHEMBL22976
2,6-dimethyl-pyridine
L0067
A801883
STL163956
BBL013176
AKOS005716680
unii-15fq5d0t3p
15fq5d0t3p ,
FT-0610735
2,6-lutidine [mi]
2,6-dimethylpyridine [fhfi]
dimethylpyridine, 2,6-
2,6-lutidine [hsdb]
BP-30085
SCHEMBL9611
2,6 lutidine
2-6-lutidine
2,6lutidine
2,6-dimethyl pyridine
2,6- lutidine
lutidin
2,6 -lutidine
2,6-dimethyl pyridin
2.6-dimethylpyridine
2,6-lutidene
2.6-lutidine
2,6-dimethylpiridine
tox21_303862
NCGC00357127-01
dtxcid1030109
dtxsid7051557 ,
cas-108-48-5
Q-100049
.alpha.,.alpha.'-lutidin
mfcd00006345
F0001-0171
alpha,alpha'-lutidin
2,6-lutidine, analytical standard
2,6-dimethylpyridine, redistilled
2,6-lutidine, 8ci
fema 3540
135742-47-1
2,6-dimethylpyridine-d9
2,6-litidine-d6
Q209284
AM10711
2,6-lutidine (8ci); 2,6-dimethylpyridine; nsc 2155; ?,?'-dimethylpyridine; ?,?'-lutidine
BP-31131
Z104472820
F91703
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30518Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30385Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (24.00)18.7374
1990's0 (0.00)18.2507
2000's6 (24.00)29.6817
2010's11 (44.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.80 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index89.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]